Headline: Sangamo Therapeutics (SGMO) Files for Chapter 11, Sells Key Assets

Sangamo Therapeutics (SGMO) filed for Chapter 11 bankruptcy protection on June 23, 2026, simultaneously announcing agreements to sell its oncology and neurology assets. The strategic move aims to facilitate an orderly wind-down of operations and maximize value for stakeholders amidst financial restructuring. Under the terms, Sanofi will acquire Sangamo's oncology assets, while a newly formed entity will purchase its neurology assets. CEO Sandy Macrae stated these actions follow a comprehensive review of strategic alternatives, underscoring the company's commitment to its stakeholders.